Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects

Area of Science:

• Hepatobiliary Cancers
• Medical Oncology
• Translational Research

Background:

• Hepatocellular carcinoma (HCC) treatment has evolved from local therapies to systemic drug regimens.
• Recent advancements include immunotherapy and targeted therapies, significantly improving patient prognoses.
• The integration of systemic and local treatments is enabling earlier curative interventions.

Purpose of the Study:

• To review current evidence on systemic drug therapy for hepatocellular carcinoma (HCC).
• To discuss evolving treatment strategies, including novel drug combinations and local therapy integration.
• To explore future prospects and the need for a resectability classification system in HCC.

Main Methods:

• Comprehensive literature review of clinical trials and evidence for HCC drug therapies.
• Analysis of treatment paradigm shifts from monotherapy to combination regimens.
• Evaluation of the impact of new therapies on patient outcomes and resectability.

Main Results:

• Systemic therapies, particularly immunotherapy combinations like atezolizumab and bevacizumab, have markedly improved HCC patient survival.
• Combination of systemic drugs with local therapies (e.g., transarterial chemoembolization) enhances treatment efficacy and curability.
• Previously unresectable HCC cases are becoming amenable to surgical resection after systemic treatment.

Conclusions:

• The landscape of HCC treatment has been transformed by effective systemic therapies, expanding therapeutic options.
• Future strategies involve optimizing treatment combinations and developing standardized resectability criteria.
• Continued research and clinical trials are crucial for advancing HCC management and improving patient outcomes.